The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma

Melanoma is responsible for 90% of skin cancer-related deaths. Major therapeutic advances have led to a considerable improvement in the prognosis of patients, with the development of targeted therapies (BRAF or MEK inhibitors) and immunotherapy (anti-CTLA-4 or -PD-1 antibodies). However, the tumor c...

Descripción completa

Detalles Bibliográficos
Autores principales: Gauci, Marie-Léa, Giustiniani, Jérôme, Lepelletier, Clémence, Garbar, Christian, Thonnart, Nicolas, Dumaz, Nicolas, Foussat, Arnaud, Lebbé, Céleste, Bensussan, Armand, Marie-Cardine, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519731/
https://www.ncbi.nlm.nih.gov/pubmed/35428910
http://dx.doi.org/10.1007/s00262-022-03199-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519731/
https://www.ncbi.nlm.nih.gov/pubmed/35428910
http://dx.doi.org/10.1007/s00262-022-03199-0

Ejemplares similares